Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Opioid Analgesics Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Opioid Analgesics Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Opioids (Narcotic analgesics) are a class of medicines that are used to provide relief from moderate-to-severe acute or chronic pain. Opioids act both presynaptically and postsynaptically to produce an analgesic effect. Presynaptically, opioids block calcium channels in nociceptive afferent nerves to inhibit the release of neurotransmitters such as the substance P and glutamate, which contribute to nociception. Postsynaptically, opioids open potassium channels, which hyperpolarizes cell membranes, increasing the required action potential to generate nociceptive transmission. The mu, kappa, and delta-opioid receptors mediate analgesia spinally and supraspinally. Opioids can be used in hospital settings to relieve pain from myocardial infarction, sickle cell crisis, pain associated with pre-and postoperative surgical conditions, trauma, severe chronic pain in cancer, pain from kidney stones, and severe back pain. Purdue Pharma, J&J Services, Hikma Pharmaceuticals, Pfizer, AbbVie, Sanofi, and Sun Pharmaceuticals are some of the key players in the opioid analgesics market.
Key Developments
Approved Opioid Analgesics
Drugs under the Pipeline for Opioid Analgesics
Clinical Activity and Development of Opioid Analgesics
Currently, there are more than 25 drug products in the opioid analgesic segment in the market. Moreover, about 20 pharmaceutical companies have their products in the pipeline for studying new indications of opioid analgesics.
|
Molecule Name |
Number of Studies |
|
TRN-228 (Cebranopadol) |
13 |
|
JNS020QD (Fentanyl) |
1 |
|
GRT9906 PR |
3 |
|
OX27 |
1 |
Opioid analgesics are generally indicated as an adjunct to general anesthesia. In epidural anesthesia or intrathecal analgesia, for palliative care, opioids acts as an antitussive for severe cough and antidiarrheal in chronic conditions. Additionally, there are studies going on about the use of opioid analgesics for conditions like acute ischemic stroke, long-term postoperative sleep disturbances, labor pain, endoscopic hemostasis, intraoperative hypotension, osteoarthritis, colorectal surgery, septic shock, adolescent idiopathic scoliosis, and others.
Orexo’s Zubsolv has seen total sales of US$ 58 million, while in the USA alone the sales were US$ 53 million. Abstral is another opioid analgesic of Orexo company, which patents for Europe and the USA expired in Oct 2019 and the patents are still valid until Sep 2024 in Japan and Australia. AcelRx Pharmaceuticals’s Dsuvia’s net sales for 2022 were US$ 1.8 million, representing an increase of 76% over the same period in 2021. In 2021, consumption of Morphine was the highest in Europe (39.4%), followed by the USA (33.4%), Australia and New Zealand (7.9%), Canada (4.5%), Japan (0.5%), and others (14.3%). According to World Drug Report 2019, about 9.3 million people in the USA misused pharmaceutical opioids which included hydrocodone (5.1 million people), oxycodone (3.2 million), and fentanyl products (0.26 million).
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Abstral (Fentanyl sublingual tablets), Dilaudid (Hydromorphone), Stadol (Butorphanol), Demerol (Meperidine), Zohydro ER (Hydrocodone), Nubain (Nalbuphine), Dolophine (Methadone), Darvon (Propoxyphene), Talwin (Pentazocine), Duragesic (Fentanyl) are some of the approved opioid analgesics.
The global sale of Zubsolv for 2022 was US$ 58 million.
Purdue Pharma, J&J Services, Hikma Pharmaceuticals, Pfizer, AbbVie, Sanofi, and Sun Pharmaceuticals are a few major players in the opioid analgesics space.
Acute ischaemic stroke, long-term postoperative sleep disturbances, labor pain, endoscopic hemostasis, intraoperative hypotension, osteoarthritis, colorectal surgery, septic shock, and adolescent idiopathic scoliosis are some of the indications companies could focus on for the expansion of the opioid analgesics market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.